Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.60 |
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6000086 | 0.98 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL1059693 | 0.84 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL10349948 | 0.84 | NPC1 (0.57) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL757031 | 0.82 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL30037937 | 0.82 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL844728 | 0.82 | SMN1; SMN2 (0.49) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL285358 | 0.81 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL104281 | 0.81 | HDAC6 (0.61) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL243922 | 0.81 | LMNA (0.61) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL2929122 | 0.81 | MAPT (0.66) | RAB9ANPC1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015339-A1 | CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY | UNIVERSITE GRENOBLE ALPES (FR) | 2026-01-15 | — | — | US | disclosed |
| EP-4655285-A1 | CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY | Université Grenoble Alpes (FR) | 2025-12-03 | — | — | EP | disclosed |
| EP-4249470-B1 | METHOD FOR PREPARING ALPHA-AMINO ACIDS | PHILIPPS UNIV MARBURG (DE) | 2024-11-13 | — | — | EP | disclosed |
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | CONFO THERAPEUTICS N.V. (BE) | 2024-11-07 | — | — | US | disclosed |
| CN-114507246-B | Benzimidazole substituted amino phenol oxygen zinc halide, and preparation method and application thereof | 华东理工大学 | 2024-09-24 | — | — | CN | disclosed |
| CN-118684676-A | Heterocyclic compound, and preparation method and application thereof | 上海济煜医药科技有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024156819-A1 | CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY | UNIVERSITE GRENOBLE ALPES (FR) | 2024-08-02 | — | — | WO | disclosed |
| EP-4406939-A1 | CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY | Université Grenoble Alpes (FR) | 2024-07-31 | — | — | EP | disclosed |
| CN-118159530-A | Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling | 康福治疗有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240180907-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-06-06 | — | — | US | disclosed |
| CN-86108308-A | Heterocycle oxo-2 guanidine-acetic acid | — | 1987-07-15 | — | — | CN | disclosed |
| EP-0226342-A1 | 5-Phenyl-2-oxazole derivatives as anti-inflammatory/antiallergic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-06-24 | — | — | EP | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
| EP-0014411-B1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLYLBENZOFURANS | BAYER AG (DE) | 1981-10-07 | — | — | EP | disclosed |
| US-4268670-A | Process for the preparation of benzimidazolylbenzofuranes | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-19 | — | — | US | disclosed |
| US-4251619-A | Process for forming photo-polymeric image | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1981-02-17 | — | — | US | disclosed |
| EP-0014411-A1 | Process for the preparation of benzimidazolylbenzofurans | BAYER AG (DE) | 1980-08-20 | — | — | EP | disclosed |
| EP-0012291-A1 | Process for the preparation of benzimidazolyl benzofuranes | BAYER AG (DE) | 1980-06-25 | — | — | EP | disclosed |
| US-4140852-A | WHITENING | BAYER AKTIENGESELLSCHAFT (DE) | 1979-02-20 | — | — | US | disclosed |
| US-3957513-A | Method of free radical photography utilizing a short light flash for exposure | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015339-A1 | CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY | CBR1, CYP4X1, CBR3 | RAB9A 3347/4885NPC1 289/4885SMN1; SMN2 2691/4885 |
| US-20240180907-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | RAB9A 3696/4885NPC1 747/4885SMN1; SMN2 2204/4885 |
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | AGTR2, AGTR1, OPRL1 | RAB9A 2496/4885NPC1 1380/4885SMN1; SMN2 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.